NRx Pharmaceuticals, Inc. (NRXP)

0.7250 -0.0022 (-0.30%) At close: 04:00PM EDT

NRx Pharmaceuticals, Inc.

1201 Orange Street
Suite 600
Wilmington, DE 19801
United States
484 254 6134
https://www.nrxpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jonathan C. Javitt M.D., M.P.H.	Co-Founder, Chief Scientist & Director	377.29k	N/A	1957
Mr. Robert Besthof M.I.M.	Head of Operations, Chief Commercial & Patient Officer	264k	N/A	1966
Mr. Stephen H. Willard Esq.	CEO & Director	N/A	N/A	1961
Prof. Daniel C. Javitt	Co-Founder & Chairman of Scientific Advisory Board	N/A	N/A	N/A
Dr. Seth L. Van Voorhees Ph.D.	CFO & Treasurer	N/A	N/A	1961
Suzanne Messere	Investor Relations	N/A	N/A	N/A
Dr. Michael Kunz	Gen. Counsel & Corp. Sec.	N/A	N/A	1965
Ms. Molly Cogan	Sr. Director of Global Communications & Gov. Affairs	N/A	N/A	N/A
Dr. Philip T. Lavin Ph.D.	Chief Methodologist	N/A	N/A	1947
Dr. Dennis K. McBride Ph.D.	Chief Strategy Officer & Sr. Scientist	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Corporate governance

NRx Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.